[HTML][HTML] Availability and costs of medicines for the treatment of tuberculosis in Europe
G Günther, L Guglielmetti, C Leu, C Lange… - Clinical microbiology …, 2023 - Elsevier
Objectives To evaluate the access to comprehensive diagnostics and novel antituberculosis
medicines in European countries. Methods We investigated the access to genotypic and …
medicines in European countries. Methods We investigated the access to genotypic and …
Availability and costs of medicines for the treatment of tuberculosis in Europe.
G Günther, L Guglielmetti, CP Leu, C Lange… - Clinical microbiology …, 2023 - boris.unibe.ch
OBJECTIVES To evaluate the access to comprehensive diagnostics and novel anti-
tuberculosis medicines in European countries. METHODS We investigated access to …
tuberculosis medicines in European countries. METHODS We investigated access to …
[PDF][PDF] Availability and costs of medicines for the treatment of tuberculosis in Europe
G Günther, L Guglielmetti, C Leu, C Lange, F van Leth - scholar.archive.org
Results: Overall, 43 treatment centers in 43 countries participated in the study. 45 For WHO
Group A drugs, the frequency of countries with availability of phenotypic drug 46 …
Group A drugs, the frequency of countries with availability of phenotypic drug 46 …
[PDF][PDF] Availability and costs of medicines for the treatment of tuberculosis in Europe
G Günther, L Guglielmetti, C Leu, C Lange - 2022 - academia.edu
abstract Objectives: To evaluate the access to comprehensive diagnostics and novel
antituberculosis medicines in European countries. Methods: We investigated the access to …
antituberculosis medicines in European countries. Methods: We investigated the access to …
Availability and costs of medicines for the treatment of tuberculosis in Europe
G Gunther, L Guglielmetti, C Leu… - Clinical Microbiology and …, 2023 - ibn.idsi.md
Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis
medicines in European countries. Methods: We investigated the access to genotypic and …
medicines in European countries. Methods: We investigated the access to genotypic and …
Availability and costs of medicines for the treatment of tuberculosis in Europe
G Günther, L Guglielmetti, C Leu, C Lange… - Clinical Microbiology …, 2023 - research.rug.nl
Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis
medicines in European countries. Methods: We investigated the access to genotypic and …
medicines in European countries. Methods: We investigated the access to genotypic and …
Availability and costs of medicines for the treatment of tuberculosis in Europe
G Günther, L Guglielmetti, C Leu, C Lange… - Clinical Microbiology …, 2022 - hal.science
Availability and costs of medicines for the treatment of tuberculosis in Europe - Archive ouverte
HAL Accéder directement au contenu Documentation FR Français (FR) Anglais (EN) Se …
HAL Accéder directement au contenu Documentation FR Français (FR) Anglais (EN) Se …
Availability and costs of medicines for the treatment of tuberculosis in Europe.
G Günther, L Guglielmetti, C Leu, C Lange, F van Leth - 2023 - cabidigitallibrary.org
Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis
medicines in European countries. Methods: We investigated the access to genotypic and …
medicines in European countries. Methods: We investigated the access to genotypic and …
[PDF][PDF] Availability and costs of medicines for the treatment of tuberculosis in Europe
G Günther, L Guglielmetti, C Leu, C Lange, F van Leth - researchgate.net
Results: Overall, 43 treatment centers in 43 countries participated in the study. 45 For WHO
Group A drugs, the frequency of countries with availability of phenotypic drug 46 …
Group A drugs, the frequency of countries with availability of phenotypic drug 46 …
Availability and costs of medicines for the treatment of tuberculosis in Europe.
G Günther, L Guglielmetti, C Leu, C Lange… - … and Infection: the …, 2022 - europepmc.org
Methods We investigated the access to genotypic and phenotypic Mycobacterium
tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and …
tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and …